Cure51

Liberté, Égalité, Fraternité… and a shared commitment to advance cancer research

Why do exceptional survivors hold the blueprint to defeating cancer?

New strategic partnerships: our global oncology network continues to expand!

Emna Makhlouf, Chief of Staff: "Working with cancer survivors gives a lot of purpose to what we do"

Sharing Insights: our CEO Nicolas Wolikow Speaks at PSCC Annual Event!

The Rosalind Study | Three cohorts, one mission: decoding exceptional Cancer survival across GBM, ES-SCLC and mPDAC

How Cure51 Builds a Global Cancer Research Project Across 50+ Countries

Working hand in hand with patient advocates to advance Pancreatic Cancer Research

A Strategic Partnership to Rethink Pancreatic Cancer Treatment: Cure51 × CRCM × Institut Paoli-Calmettes

Simon Istolainen and Nicolas Wolikow: The History of Cure51 and the Vision Behind a New Model in Oncology

Rosalind Study Milestone: 115+ Centers Join Cure51’s International Oncology Network

Cure51's CEO Nicolas Wolikow: "Reverse-Engineering the Cure to Cancer: A New Paradigm in Oncology Research"